
- Telehealth Visits
- Insurance plan information


Devanand Manoli, MD, PhD
Pediatric Psychiatry- Telehealth Visits
- Insurance plan information




Devanand Manoli, MD, PhD
Pediatric Psychiatry- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Devanand Manoli is a psychiatrist who specializes in caring for children and adolescents. With a background in neuroscience, he has expertise in understanding social behaviors in terms of the activity of the neural circuits that mediate social behavior, and in the context of psychiatric illness.
In his research, Manoli seeks to understand social attachment, using molecular and genetic approaches to study its neural basis throughout development and in the context of environmental and genetic factors that are associated with neuropsychiatric disorders.
Manoli earned his medical degree and a doctorate in neuroscience at Stanford University. He completed a residency in general psychiatry and a fellowship in child and adolescent psychiatry at UCSF.
Education & training
Board certification
- Child & Adolescent Psychiatry, American Board of Psychiatry and Neurology
- Psychiatry, American Board of Psychiatry and Neurology
Fellowship
- Child and Adolescent Psychiatry, UCSF Graduate Medical Education
Residency
- Psychiatry, UCSF Graduate Medical Education
Degree
- MD, Stanford University School of Medicine
My expertise
Specialties
- Pediatric Psychiatry
Clinical Trials query: q=health_gateway_id_ss%3A%28%221422%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%221422%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.